Legend Biotech Corporation (LEGN)
NASDAQ: LEGN · Real-Time Price · USD
34.08
+0.06 (0.18%)
Dec 20, 2024, 4:00 PM EST - Market closed
Legend Biotech Revenue
Legend Biotech had revenue of $160.21M in the quarter ending September 30, 2024, with 66.86% growth. This brings the company's revenue in the last twelve months to $520.18M, up 122.96% year-over-year. In the year 2023, Legend Biotech had annual revenue of $285.14M with 143.70% growth.
Revenue (ttm)
$520.18M
Revenue Growth
+122.96%
P/S Ratio
11.95
Revenue / Employee
$284,876
Employees
1,826
Market Cap
6.25B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Grifols | 7.81B |
Bausch + Lomb | 4.68B |
Elanco Animal Health | 4.45B |
Jazz Pharmaceuticals | 3.99B |
Lantheus Holdings | 1.50B |
Halozyme Therapeutics | 947.36M |
Waystar Holding | 906.14M |
Revolution Medicines | 742.00K |
LEGN News
- 2 days ago - Legend Biotech to Present at the 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 12 days ago - CARVYKTI® Significantly Improved Minimal Residual Disease Negativity Compared to Standard of Care for Patients with Relapsed or Refractory Multiple Myeloma - GlobeNewsWire
- 16 days ago - Legend Biotech: The Story Brightens - Seeking Alpha
- 5 weeks ago - Legend Biotech Corporation (LEGN) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Legend Biotech to Host Investor Event During the 66th American Society of Hematology (ASH) Annual Meeting and Exposition - GlobeNewsWire
- 6 weeks ago - Legend Biotech to Unveil Minimal Residual Disease Data from Landmark CARTITUDE-4 Trial in Multiple Myeloma - GlobeNewsWire
- 6 weeks ago - Legend Biotech Appoints Alan Bash as President of CARVYKTI® - GlobeNewsWire
- 2 months ago - Stock Picks From Seeking Alpha's September 2024 New Analysts - Seeking Alpha